Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

Revuforj® (revumenib) is a menin inhibitor and blocks the interaction of both wild-type KMT2A and KMT2A fusion proteins with menin. The binding of KMT2A fusion proteins with menin is involved in KMT2A ...

(MENAFN- JCN NewsWire) Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract ...

gene fusion, gene fission, and de novo origination. Gene duplication, in particular, plays a pivotal role in creating new genes, with over 100 genes duplicating in the human genome every million years ...

NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment ...

HCW Biologics entered into License, Research and Co-Development Agreement HCW Biologics to receive upfront payment of $7 ...

Researchers developed a barcoded directed evolution system for engineered virus-like particles (eVLPs), creating a ...

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

A breakthrough tool called Helicase-Assisted Continuous Editing (HACE) allows scientists to create precise genetic mutations ...

Five companies joined The Crunchbase Unicorn Board in October 2024, across sectors spanning AI, energy, robotics, fintech and ...

The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.